Last reviewed · How we verify
NCT05520294
Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
trial testing High-performance liquid chromatography-tandem mass spectrometry assays in Melanoma in 90 participants. Participants enrolled and being followed up; not accepting new ones.
31 August 2024
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 September 2022 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- High-performance liquid chromatography-tandem mass spectrometry assays
Conditions studied
- Melanoma — all drugs for Melanoma →
Sponsor
University of Colorado, Denver
Who can join
Adults 21 to 100, any sex, with Melanoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this proposal is to determine how cannabinoid use affects the tumor immune microenvironment (TME) of melanoma by correlating TILs with reported cannabinoid use and circulating plasma cannabinoids. The central hypothesis is that cannabinoid use decreases TILs in melanoma in a dose-dependent fashion. This is important because cannabinoid-driven TME changes in melanoma may alter patient outcomes mediated by TILs and response to standard of care ICI treatments.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Cannabinoids in Treating Chemotherapy-Induced Nausea and Vomiting, Cancer-Associated Pain, and Tumor Growth.
Bathula PP, Maciver MB. · · 2023 · cited 18× · PMID 38203245 · DOI 10.3390/ijms25010074 -
The Role of Cannabinoids in Advancing Cancer Treatment: Insights from Evidence-Based Medicine.
Skórzewska M, Gęca K. · · 2024 · cited 6× · PMID 39110350 · DOI 10.1007/s11912-024-01589-4 -
Calcium channels as pharmacological targets for cancer therapy.
Liu X, Feng C, Yan L, Cao J, et al · · 2025 · cited 3× · PMID 40131496 · DOI 10.1007/s10238-025-01632-z
Verify or expand the search:
- PubMed search for NCT05520294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
- NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05520294 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 17 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05520294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing